Shanghai Securities News reported on December 20 that BaiKe Biological announced in the evening that it recently received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration, granting permission to conduct clinical trials for the prevention of genital herpes caused by Herpes Simplex Virus Type 2 (HSV-2) infection.

The HSV-2 vaccine approved for clinical trials by the company was jointly submitted with Zhuhai Lifanda Biotechnology Co., Ltd. This vaccine is a multi-component vaccine capable of inducing both humoral immune responses and cellular immune responses, utilizing mRNA technology to further enhance the cellular immune response. Compared to traditional technology routes, it increases the likelihood of successful vaccine development.

As of now, there are no related vaccine products successfully developed and marketed globally. BaiKe Biological stated that if this vaccine successfully completes its clinical trials and receives market approval, it will further enrich the company's product pipeline, help optimize product structure and industrial layout, and promote the comprehensive development of its main business, thereby enhancing the company's long-term profitability and better meeting market demand.

https://finance.eastmoney.com/a/202412203274601849.html